Trials / Completed
CompletedNCT00489294
Safety Study of Syntropin (Human Growth Hormone) for the Treatment of Growth Hormone Deficiency
An Open-Label Study of the Pharmacokinetics and Pharmacodynamics of Syntropin (a Human Growth Hormone) in Growth Hormone-Suppressed Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Phage Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics of Syntropin (a human growth hormone) and to determine the serum concentration of IGF-1 after Syntropin injection.
Detailed description
Syntropin will be administered by subcutaneous injection. Eligible patients will receive a subcutaneous injection of octreodite (to suppress endogenous growth hormone secretion) 12 hours before, immediately prior to, and 12 hours after the scheduled injection of growth hormone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Syntropin |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-06-01
- Completion
- 2005-06-01
- First posted
- 2007-06-21
- Last updated
- 2012-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00489294. Inclusion in this directory is not an endorsement.